BioMarin Pharmaceutical (BMRN) investor relations material

Strategic overview and recent performance

• Focus remains on rare, genetically defined diseases, with nine approved therapies and six first-in-disease medicines.

• Achieved nearly $1 billion in Q2 revenue, representing 20% year-over-year growth, and raised full-year revenue guidance to $3.875–$3.925 billion.

• Operating in over 80 countries, leveraging in-house manufacturing and global commercial capabilities.

• Recent transformation improved profitability and cash flow, supporting reinvestment in growth.

Amicus acquisition and integration

• Closed acquisition of Amicus Therapeutics, adding Galafold and Pombiliti/Opfolda, with peak revenue targets of $1.4B and $1.2B by mid-to-late 2030s.

• Expect to realize 50% cost synergies from Amicus, mainly in G&A, while investing in sales and marketing to preserve growth.

• Accelerated de-leveraging target to less than 2.5x leverage by mid-2025, one year ahead of plan, due to strong revenue and synergy realization.

• Amicus business projected to reach 60% operating margin by 2030, enhancing overall profitability.

Commercial execution and growth drivers

• Global expansion of Galafold and Pombiliti is a key growth lever, leveraging BioMarin’s presence in 80 markets versus Amicus’s prior reach.

• For Galafold, under-diagnosis of Fabry disease presents opportunity, with initiatives like AI-enabled patient identification and genetic screening.

• Pombiliti/Opfolda strategy focuses on switching from existing therapies, supported by emerging real-world evidence and expanded market access.